Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
12/
26
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
A study found that Repatha® (evolocumab) significantly reduced LDL cholesterol in patients with and without elevated triglycerides compared to placebo and Zetia® (ezetimibe). Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association.